Plus therapeutics presents positive phase 1 data from respect-gbm clinical trial at the european society for medical oncology congress 2022

Phase 1 data indicates that direct administration of 186 rnl targeted radiotherapeutic is safe in patients with recurrent glioblastoma

pstv Ratings Summary

pstv Quant Ranking